*In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly via subcutaneous injection, the FDA-approved formulation later marketed under the brand name Wegovy for chronic weight management in adults with obesity or overweight and at least one weight-related condition
(The most prescribed GLP-1RA was semaglutide, followed by dulaglutide and tirzepatide.) GLP-1-prescribed groups continued to show lower 1-year mortality, both without and with OSA
In some cases, counterfeit GLP-1 drugs are illegally marketed as authentic but instead contain harmful or incorrect ingredients, or have too little, too much or no active ingredient at all
Valencia: SEMM 2013 [actualizado febrero 2013
As an example, GSH depletion has been shown to promote pro-inflammatory microglial phenotypes and amplify astrocyte-microglia crosstalk (Vilhardt et al., 2017)